Literature DB >> 22959702

Impact of multiple antigenic epitopes from ApoB100, hHSP60 and Chlamydophila pneumoniae on atherosclerotic lesion development in Apob(tm2Sgy)Ldlr(tm1Her)J mice.

Xinjie Lu1, Min Xia, Valeria Endresz, Ildiko Faludi, Andrea Szabo, Eva Gonczol, Lakshmi Mundkur, Daxin Chen, Vijay Kakkar.   

Abstract

AIMS: To assess whether immunizing Apob(tm2Sgy)Ldlr(tm1Her)J mice simultaneously with different atherosclerosis-related epitopes engineered in a single recombinant protein is effective in reducing atherosclerotic lesions. METHODS AND
RESULTS: Antigenic epitopes were incorporated into a dendroaspin scaffold: AHC (ApoB100 peptide + hHSP60 peptide [hHSP60(153-163)] + putative epitope derived from Chlamydophila pneumoniae [Cpn]) and AHHC (AHC + hHSP60(303-312)); and were compared with construct A (ApoB peptide), construct H (hHSP60(153-163)), and construct AH (ApoB100 peptide + hHSP60(153-163)). Immunization with 2 multiple-antigenic epitope constructs elicited high levels of antibodies against each epitope in Apob(tm2Sgy)Ldlr(tm1Her)J mice (apart from hHSP60(153-163), which induced a low antibody response). Histological analyses demonstrated that the mice immunized with AHHC and AHC showed significant reductions in the size of atherosclerostic lesions compared with controls (63.8% and 63.2%; P < 0.001, respectively), and significantly greater reductions in lesions size compared with those after immunization with construct A (24.9%; P < 0.01), H (26.8%; P < 0.05), and AH (42.9%; P < 0.001). Moreover, combination of 2 short Cpn peptides along with ApoB and hHSP60 peptides had an additive effect on reducing the lesion without Cpn infection. Reduction in plaque size correlated with cellular infiltration and cytokine/chemokine secretion in serum or by stimulated spleen cells as well as specific cellular immune responses when compared with controls.
CONCLUSIONS: Immunization of mice with a single construct containing multiple epitopes derived from ApoB100, hHSP60 and Cpn was more effective in reducing early atherosclerotic lesions through the induction of a specific Treg-cell response than was the construct containing either mono- or bi-epitopes. This approach offers attractive opportunities for the design of protein-based, multivalent vaccines against atherosclerosis.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22959702     DOI: 10.1016/j.atherosclerosis.2012.07.021

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  11 in total

Review 1.  Vaccine against arteriosclerosis: an update.

Authors:  Kuang-Yuh Chyu; Paul C Dimayuga; Prediman K Shah
Journal:  Ther Adv Vaccines       Date:  2017-02-01

Review 2.  Tolerization against atherosclerosis using heat shock protein 60.

Authors:  Cecilia Wick
Journal:  Cell Stress Chaperones       Date:  2015-11-17       Impact factor: 3.667

3.  A clinically applicable adjuvant for an atherosclerosis vaccine in mice.

Authors:  Kouji Kobiyama; Melanie Vassallo; Jessica Mitzi; Holger Winkels; Hong Pei; Takayuki Kimura; Jacqueline Miller; Dennis Wolf; Klaus Ley
Journal:  Eur J Immunol       Date:  2018-08-12       Impact factor: 5.532

4.  Antibody to oxidized low-density lipoprotein inhibits THP1 cells from apoptosis by suppressing NF-κB pathway activation.

Authors:  Rui Dai; Jing Dong; Weijuan Li; Yi Zhou; Wei Zhou; Wenping Zhou; Manhua Chen
Journal:  Cardiovasc Diagn Ther       Date:  2019-08

5.  Modulation of recombinant antigenic constructs containing multi-epitopes towards effective reduction of atherosclerotic lesion in B6;129S-Ldlr(tm1Her)Apob(tm2Sgy)/J mice.

Authors:  Min Xia; Daxin Chen; Valeria Endresz; Ildiko Lantos; Andrea Szabo; Vijay Kakkar; Xinjie Lu
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

6.  Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.

Authors:  Gergana Galabova; Sylvia Brunner; Gabriele Winsauer; Claudia Juno; Bettina Wanko; Andreas Mairhofer; Petra Lührs; Achim Schneeberger; Arne von Bonin; Frank Mattner; Walter Schmidt; Guenther Staffler
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

7.  Immune regulation by oral tolerance induces alternate activation of macrophages and reduces markers of plaque destabilization in Apobtm2Sgy/Ldlrtm1Her/J mice.

Authors:  Lakshmi Narasimha Thota; Thiruvelselvan Ponnusamy; Sheena Philip; Xinjie Lu; Lakshmi Mundkur
Journal:  Sci Rep       Date:  2017-06-21       Impact factor: 4.379

Review 8.  Vaccination in Atherosclerosis.

Authors:  Felix Sebastian Nettersheim; Lauren De Vore; Holger Winkels
Journal:  Cells       Date:  2020-11-30       Impact factor: 6.600

9.  Immunization of Chlamydia pneumoniae (Cpn)-infected Apob(tm2Sgy)Ldlr(tm1Her)/J mice with a combined peptide of Cpn significantly reduces atherosclerotic lesion development.

Authors:  Min Xia; Daxin Chen; Valeria Endresz; Ildiko Faludi; Andrea Szabo; Eva Gonczol; Vijay Kakkar; Xinjie Lu
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

Review 10.  Regulatory T Cell-Enhancing Therapies to Treat Atherosclerosis.

Authors:  Hafid Ait-Oufella; Jean-Rémi Lavillegrand; Alain Tedgui
Journal:  Cells       Date:  2021-03-24       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.